TNFRSF1B and neoplasm: Interestingly, the TNFR2-PLGA-ADR treatment dramatically decreased intratumoral Tregs to 15.1% in CT26 tumor and 13.8% in MC38 tumor (Fig. 7A and B; P < 0.001), and the abundance of TNFR2 expression was markedly reduced as well (Fig. 7C; P < 0.001).